We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
-0.18%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$383M
AUM Growth
+$150M
Cap. Flow
+$155M
Cap. Flow %
40.41%
Top 10 Hldgs %
48.06%
Holding
163
New
56
Increased
35
Reduced
10
Closed
61

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.5M
2
LLY icon
Eli Lilly
LLY
+$16.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.45M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$7.89M
5
ARGX icon
argenx
ARGX
+$7.32M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$9.05M
2
ABBV icon
AbbVie
ABBV
+$8.88M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$6.68M
4
BPMC
Blueprint Medicines
BPMC
+$5.6M
5
AZN icon
AstraZeneca
AZN
+$3.93M

Sector Composition

Rank Sector Weight
1 Healthcare 32.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
151
Teva Pharmaceuticals
TEVA
$39.5B
– –
-300,000
Closed -$6.68M
TGTX icon
152
PUT
TG Therapeutics
TGTX
$7.27B
– –
-200,000
Closed -$6.02M
VIR icon
153
CALL
Vir Biotechnology
VIR
$1.49B
– –
-100,000
Closed -$734K
VRTX icon
154
CALL
Vertex Pharmaceuticals
VRTX
$120B
– –
-57,400
Closed -$23.1M
WAVE
155
CALL
Eco Wave Power Global
WAVE
$47.9M
– –
-23,600
Closed -$292K
XBI icon
156
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.67B
– –
-200,000
Closed -$18M
ZVRA icon
157
Zevra Therapeutics
ZVRA
$574M
– –
-42,081
Closed -$351K
QTTB icon
158
CALL
Q32 Bio
QTTB
$466M
– –
-5,600
Closed -$19.3K
QTTB icon
159
Q32 Bio
QTTB
$466M
– –
-19,700
Closed -$67.8K
QTTB icon
160
PUT
Q32 Bio
QTTB
$466M
– –
-35,100
Closed -$121K
ONC
161
BeOne Medicines Ltd
ONC
$32.3B
– –
-30,000
Closed -$422K
CMRX
162
DELISTED
Chimerix, Inc.
CMRX
– –
-29,082
Closed -$101K
ITCI
163
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-43,700
Closed -$3.65M
3 4 5 6
7

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Diadema Partners held 163 positions worth $383M, up 64% from $233M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Diadema Partners deployed $155M of net new capital in Q1 2025, opening 56 new positions and adding to 35 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $2.42M trimmed.

  • Diadema Partners's largest Q1 2025 buy was Regeneron Pharmaceuticals: 29,828 shares worth $18.9M.
  • Diadema Partners added most to Jazz Pharmaceuticals in Q1 2025, an estimated $9.45M increase.
  • Diadema Partners's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $2.42M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q1 2025, selling an estimated $9.05M.
  • Diadema Partners's ten largest holdings make up 48% of its $383M portfolio in Q1 2025.
  • Diadema Partners opened 56 new positions and closed 61 in Q1 2025.
  • Diadema Partners's portfolio value rose 64% quarter-over-quarter to $383M.

Based on Diadema Partners's 13F filing for Q1 2025, filed 15 May 2025.